To the full analysis
Amphastar Pharmaceuticals stock: growth
AMPHAmphastar Pharmaceuticals reported $719.89M in revenue for fiscal 2025, down 1.7% on the prior year, up 15.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.8%
per year from 2011 to 2025, per share 0.3%
Earnings (Annual rate)
19.9%
per year from 2011 to 2025, per share 5.7%
Free cash flow (Annual rate)
21%
per year from 2011 to 2025, per share 6.7%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2011 | |
|---|---|---|---|
| Revenue | 15.5% | 11.1% | 13.8% |
| Revenue per share | 15.7% | 10.7% | 0.3% |
| Earnings | 133.8% | no data | 19.9% |
| Earnings per share | 134.2% | no data | 5.7% |
| Free cash flow | 38.9% | no data | 21.0% |
| Free cash flow per share | 39.1% | no data | 6.7% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2011 | $118.36M | $7.75M | $8.38M |
| 2012 | $204.32M | $18.09M | −$26.9M |
| 2013 | $229.68M | $11.86M | $12.74M |
| 2014 | $210.46M | −$10.7M | $553K |
| 2015 | $251.52M | −$2.79M | −$5.37M |
| 2016 | $255.17M | $10.53M | $17.18M |
| 2017 | $240.18M | $4.51M | $4.11M |
| 2018 | $294.67M | −$5.74M | −$8.62M |
| 2019 | $322.36M | $48.94M | $207K |
| 2020 | $349.85M | $1.4M | $23.41M |
| 2021 | $437.77M | $62.12M | $70.54M |
| 2022 | $498.99M | $91.39M | $65.15M |
| 2023 | $644.4M | $137.55M | $145.34M |
| 2024 | $731.97M | $159.52M | $172.35M |
| 2025 | $719.89M | $98.09M | $121.23M |
Revenue by region
Where Amphastar Pharmaceuticals, Inc. generates its revenue.
- United States95%
- France5%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $419.87M | $486.83M | $635.19M | $707.68M | $681.42M | 94.7% |
| France | $11.88M | $7.46M | $4.7M | $19.95M | $35.28M | 4.9% |
| Other | $6.02M | $0 | $0 | $0 | $0 | 0% |
| Total revenue | $437.77M | $498.99M | $644.4M | $731.97M | $719.89M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.